Now Approved!

|

Mirataz® (mirtazapine transdermal ointment) is the FIRST AND ONLY FDA-approved transdermal medication for the management of weight loss in cats

  • In clinical studies, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2 mg per day1
  • Mirataz gives your clients a practical way to manage their cat’s weight loss without administration of oral medication and does not rely on the cat to eat to be medicated
  • Due to proprietary Accusorb technology, Mirataz achieves measurable plasma concentrations of mirtazapine in cats2
  • Mirataz was well tolerated both locally and systemically in clinical studies1

Sign up to receive future communications about Mirataz

For more information:

Call 1-888-608-2542

To place an order now:

Contact your preferred animal health distributor or to set up an account with KindredBio call 1-888-608-2542 or click here*.

*Please note: account setup may take up to 24 hours. Please expect an email to confirm setup within 24 hours.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information click here.

References: 1. Mirataz® (mirtazapine transdermal ointment) [package insert], Kindred Biosciences, Inc. (Burlingame, CA). Rev. 5/2018. 2. Buhles W, Quimby JM, Labelle D, et al. Single and multiple dose pharmacokinetics of a novel transdermal ointment in cats. J Vet Pharmacol Ther. In press 2018.

Mirataz® and Accusorb are trademarks of KindredBio
©2018 Kindred Biosciences, Inc., Burlingame, CA 94010. All rights reserved
US-MAZ-1800038 5/4/18

We believe that KindredBio has embarked on an extraordinary journey, with great benefits for animals and with attractive rewards for our investors.